Agenus Inc. (AGEN)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Discovery, Development and Manufacturing of a Comprehensive Pipeline of Immunological Agents	114.20M	103.46M	156.31M	98.02M	295.67M
Discovery, Development and Manufacturing of a Comprehensive Pipeline of Immunological Agents Growth	10.37%	-33.81%	59.47%	-66.85%	235.34%
Total	114.20M	103.46M	156.31M	98.02M	295.67M
Total Growth	10.37%	-33.81%	59.47%	-66.85%	235.34%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	113.16M	101.46M	153.34M	87.51M	288.96M
United States Growth	11.53%	-33.83%	75.22%	-69.72%	245.85%
Rest of World	1.04M	2.00M	2.98M	10.51M	6.70M
Rest of World Growth	-48.28%	-32.74%	-71.68%	56.83%	45.14%
Total	114.20M	103.46M	156.31M	98.02M	295.67M
Total Growth	10.37%	-33.81%	59.47%	-66.85%	235.34%

Data Source: S&P Global Market Intelligence Last updated: Mar 16, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 13, 2026

Data Sources Report a data error